You are the news now

THE NEWS COMMENTER

VOTE  (0)  (0)

Anti-Rheumatics Market to Reach $71.93 Bn, Globally, by 2026 at 2.9% CAGR: Allied Market Research


Added 01-23-20 10:04:02am EST - “Allied Market Research published a report, titled, "Anti-Rheumatics Market by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD's), Nonsteroidal Anti-Inflammatory Drugs (NSAID's), Corticosteroids, Uric Acid Drugs,…” - News.yahoo.com

CLICK TO SHARE

Posted By TheNewsCommenter: From News.yahoo.com: “Anti-Rheumatics Market to Reach $71.93 Bn, Globally, by 2026 at 2.9% CAGR: Allied Market Research”. Below is an excerpt from the article.

Increase in incidence of rheumatoid arthritis, surge in geriatric population, and rise in incidence of obesity across the world drive the growth of the global anti-rheumatics market.

PORTLAND, Oregon, Jan. 23, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, "Anti-Rheumatics Market by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD's), Nonsteroidal Anti-Inflammatory Drugs (NSAID's), Corticosteroids, Uric Acid Drugs, and Others), Type (Prescription-Based Drugs and Over-the-Counter Drugs): Global Opportunity Analysis and Industry Forecast, 2019–2026." According to the report, the global anti-rheumatics industry accounted for $57.22 billion in 2018, and is estimated to reach $71.93 billion by 2026, growing at a CAGR of 2.9% from 2019 to 2026.

Increase in incidence of rheumatoid arthritis, surge in geriatric population, and rise in incidence of obesity across the world drive the growth of the global anti-rheumatics market. However, side effects related to the medication and higher cost of biologics & biosimilars hinder the growth of the market. On the other hand, R&D activities in the field of biosimilars and novel biologics present numerous opportunities in the market.

Based on drug class, the disease modifying anti-rheumatic drugs (DMARDs) segment held more than one-third of the total market share of the global anti-rheumatics market in 2018, and is expected to maintain its lead position throughout the forecast period. This is due to its action on the medical conditions rather than acting on the symptoms. However, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to grow at the fastest CAGR of 3.7% from 2019 to 2026. This is attributed to the rise in incidences of rheumatoid arthritis regarding pain in the joints.

Based on type, the prescription-based drugs segment accounted for the highest share in the global anti-rheumatics market in 2018, contributing for more than three-fourths of the total share, and is estimated to maintain its dominance in terms of revenue throughout the forecast period. This is due to increase in the number of specialized hospitals across the world that provide treatment from specialized medical professionals. However, the over-the-counter drugs segment is estimated to register the highest CAGR of 3.3% from 2019 to 2026, owing to surge in awareness related to treatment options and ease in availability.

Read more...

Anonymous comments are welcome, just check the "Comment Anonymously" box before submitting your comment. Note: Comments are free and open until someone ruins it. Don't dox, promote violence, etc. Be nice and have fun.

CLICK TO SHARE

BACK TO THE HOME-PAGE